Table 3.

Correlation of Percent HIV Inhibition with Immune Mediator Concentration

Immune Mediator	Enrollment*	Return Visit 1*	Return Visit 2*	Return Visit 3*
Rho p-value	n=76	n=67	n=58	n=16
Elafin
Pregnant	−0.361	−0.535	−0.485	0.065
p-value	0.022	0.002a	0.014a	0.812
Non Pregnant	−0.437	−0.480	−0.390
p-value	0.008a	0.003a	0.025
HBD-2
Pregnant	0.271	−0.189	0.194	0.506
p-value	0.090	0.309	0.353	0.046
Non Pregnant	−0.275	−0.353	−0.485
p-value	0.104	0.035	0.004a
HBD-3
Pregnant	−0.005	0.305	0.404	0.242
p-value	0.977	0.096	0.045	0.367
Non Pregnant	−0.159	−0.103	0.005
p-value	0.355	0.552	0.978
Lactoferrin
Pregnant	0.228	0.466	0.548	0.159
p-value	0.157	0.008a	0.005a	0.556
Non Pregnant	0.431	0.256	−0.039
p-value	0.009a	0.132	0.830
LL-37
Pregnant	0.248	0.361	0.360	0.033
p-value	0.122	0.046	0.077	0.903
Non Pregnant	0.186	0.055	−0.070
p-value	0.279	0.748	0.699
MIP-3a
Pregnant	0.053	0.012	0.280	−0.072
p-value	0.748	0.950	0.175	0.790
Non Pregnant	0.165	0.231	0.203
p-value	0.337	0.175	0.257
RANTES
Pregnant	0.185	0.235	0.040	−0.553
p-value	0.253	0.203	0.851	0.026
Non Pregnant	0.059	0.088	0.064
p-value	0.732	0.608	0.725
SDF-1
Pregnant	0.190	0.531	0.526	0.261
p-value	0.240	0.002a	0.007a	0.328
Non Pregnant	0.177	0.061	−0.084
p-value	0.301	0.722	0.642
SLPI
Pregnant	−0.159	−0.374	−0.093	0.256
p-value	0.328	0.038	0.658	0.339
Non Pregnant	−0.447	−0.363	−0.391
p-value	0.006a	0.030	0.025

All rho and p-values by Spearman rank correlation

^aStatistically significant controlling for a false discovery rate of 5% for each group and time points.

^*

• Pregnancy visits: Enrollment- <14 weeks gestation
  Return visit 1- 14–28 weeks gestation
  Return visit 2- >28 weeks gestation
• Non-pregnant visits: Enrollment- Proliferative phase
  Return visit 1- Ovulatory phase
  Return visit 2- Secretory phase